Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 9/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957925 | 0.86 | UTS2R (0.39) | UTS2RHTR2CHTR2B | |
| SCHEMBL22957900 | 0.86 | LMNA (0.45) | LMNAHTR2CACACB | |
| SCHEMBL22957912 | 0.80 | RIPK1 (0.43) | LMNA | |
| SCHEMBL22957716 | 0.80 | RIPK1 (0.43) | LMNA | |
| SCHEMBL22957895 | 0.80 | RIPK1 (0.43) | LMNA | |
| SCHEMBL22957671 | 0.78 | RIPK1 (0.44) | LMNAACACB | |
| SCHEMBL24224754 | 0.77 | HTR2C (0.40) | HTR2CHTR2BACACB | |
| SCHEMBL22957789 | 0.77 | RIPK1 (0.41) | LMNA | |
| SCHEMBL22957647 | 0.77 | RIPK1 (0.45) | LMNA | |
| SCHEMBL22957656 | 0.75 | RIPK1 (0.40) | LMNAHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | UTS2R 2397/4885LMNA 3449/4885HTR2C 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.